One Biosciences, a precision oncology biotech company pioneering clinical grade single-cell tumour transcriptomic profiling, has announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.
Shutterstock.AI Generator Shutterstock
This round brings One Biosciences' total funding, to date, to over €20 million including Home Biosciences’ seed financing.
One Biosciences technology creates detailed functional profiles of patient tumours, unlocking insights that may drive better clinical decision-making, patient selection, therapy development, and potentially optimising clinical trials. Proceeds from the financing will accelerate the clinical development of One Biosciences' flagship OneMap platform and support the scaling of strategic partnerships with pharmaceutical and biotech companies.
Hedi Ben Brahim, CEO of One Biosciences, said: “This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market.”
Dr. Céline Vallot, co-founder of One Biosciences and group leader at Curie Institute, said: “This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical grade specimens.”